J Clin Oncol:ganetespib联合多西他赛治疗晚期肺腺癌

2019-12-15 QQY MedSci原创

肺腺癌是目前发生率最高的一种肺癌。Ganetespib是一种强效热休克蛋白90抑制剂,可阻断多种致癌途径,从而产生抗肿瘤活性。Pillai等人对ganetespib联合多西他赛用作二线治疗晚期肺腺癌的疗效进行评估。本研究是一项国际性的III期临床试验,招募了IIIB期或IV期的6个月前确诊的肺腺癌患者,且既往采用过一次系统治疗。将患者随机(1:1)分至ganetespib联合多西他赛组(ganet

肺腺癌是目前发生率最高的一种肺癌。Ganetespib是一种强效热休克蛋白90抑制剂,可阻断多种致癌途径,从而产生抗肿瘤活性。Pillai等人对ganetespib联合多西他赛用作二线治疗晚期肺腺癌的疗效进行评估。

本研究是一项国际性的III期临床试验,招募了IIIB期或IV期的6个月前确诊的肺腺癌患者,且既往采用过一次系统治疗。将患者随机(1:1)分至ganetespib联合多西他赛组(ganetespib:150 mg/m2,第1天和第15天;多西他赛:75 mg/m2,每个疗程的第1天,每疗程21天)或多西他赛组(仅用多西他赛)。主要结点是总体存活期(OS)。

共招募了677位患者,355位被分至联合组、337位被分至多西他赛组。由于一项计划中的中期分析无效,该试验被提前终止。联合组的中位OS时间为10.9个月,而多西他赛组的为10.5个月(风险比[HR] 1.11,95% CI 0.899-1.372,p=0.329)。联合组和多西他赛组的中位无进展存活期(PFS)分别是4.2个月和4.3个月(HR 1.16,95% CI 0.96-1.403,p=0.119)。在多西他赛的基础上额外予以ganetespib治疗并不能改善任何次要终点的预后,包括乳酸脱氢酶升高或EGFR和ALK野生型人群的存活率。两组最常见的3-4级不良事件都是中性粒细胞减少症(联合组30.9%,多西他赛组25%)。

综上所述,在多西他赛中加入ganetespib并不能提高晚期肺腺癌患者的存活率。

原始出处:

本文系梅斯医学(MedSci)原创编译,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1734194, encodeId=156d1e3419422, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Mon Nov 23 10:16:00 CST 2020, time=2020-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943244, encodeId=590f194324407, content=<a href='/topic/show?id=40875986ec9' target=_blank style='color:#2F92EE;'>#晚期肺腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59867, encryptionId=40875986ec9, topicName=晚期肺腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e72268, createdName=zhixianchen, createdTime=Fri Mar 20 05:16:00 CST 2020, time=2020-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865753, encodeId=0cb71865e53a1, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Sep 28 18:16:00 CST 2020, time=2020-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1935601, encodeId=a536193560172, content=<a href='/topic/show?id=53a3e82802' target=_blank style='color:#2F92EE;'>#ganetespib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7828, encryptionId=53a3e82802, topicName=ganetespib)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9cb02500048, createdName=ms6832696159214430, createdTime=Sun Apr 05 23:16:00 CST 2020, time=2020-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=377023, encodeId=e7173e7023fe, content=又一个失败了,Hsp90不易呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Mon Dec 16 08:53:04 CST 2019, time=2019-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1037953, encodeId=8900103e953cd, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Sun Dec 15 21:16:00 CST 2019, time=2019-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376997, encodeId=70843e6997a3, content=又多了一种新方法。, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43a21971117, createdName=njwbhuang, createdTime=Sun Dec 15 19:46:13 CST 2019, time=2019-12-15, status=1, ipAttribution=)]
    2020-11-23 canlab
  2. [GetPortalCommentsPageByObjectIdResponse(id=1734194, encodeId=156d1e3419422, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Mon Nov 23 10:16:00 CST 2020, time=2020-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943244, encodeId=590f194324407, content=<a href='/topic/show?id=40875986ec9' target=_blank style='color:#2F92EE;'>#晚期肺腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59867, encryptionId=40875986ec9, topicName=晚期肺腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e72268, createdName=zhixianchen, createdTime=Fri Mar 20 05:16:00 CST 2020, time=2020-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865753, encodeId=0cb71865e53a1, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Sep 28 18:16:00 CST 2020, time=2020-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1935601, encodeId=a536193560172, content=<a href='/topic/show?id=53a3e82802' target=_blank style='color:#2F92EE;'>#ganetespib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7828, encryptionId=53a3e82802, topicName=ganetespib)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9cb02500048, createdName=ms6832696159214430, createdTime=Sun Apr 05 23:16:00 CST 2020, time=2020-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=377023, encodeId=e7173e7023fe, content=又一个失败了,Hsp90不易呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Mon Dec 16 08:53:04 CST 2019, time=2019-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1037953, encodeId=8900103e953cd, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Sun Dec 15 21:16:00 CST 2019, time=2019-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376997, encodeId=70843e6997a3, content=又多了一种新方法。, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43a21971117, createdName=njwbhuang, createdTime=Sun Dec 15 19:46:13 CST 2019, time=2019-12-15, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1734194, encodeId=156d1e3419422, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Mon Nov 23 10:16:00 CST 2020, time=2020-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943244, encodeId=590f194324407, content=<a href='/topic/show?id=40875986ec9' target=_blank style='color:#2F92EE;'>#晚期肺腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59867, encryptionId=40875986ec9, topicName=晚期肺腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e72268, createdName=zhixianchen, createdTime=Fri Mar 20 05:16:00 CST 2020, time=2020-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865753, encodeId=0cb71865e53a1, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Sep 28 18:16:00 CST 2020, time=2020-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1935601, encodeId=a536193560172, content=<a href='/topic/show?id=53a3e82802' target=_blank style='color:#2F92EE;'>#ganetespib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7828, encryptionId=53a3e82802, topicName=ganetespib)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9cb02500048, createdName=ms6832696159214430, createdTime=Sun Apr 05 23:16:00 CST 2020, time=2020-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=377023, encodeId=e7173e7023fe, content=又一个失败了,Hsp90不易呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Mon Dec 16 08:53:04 CST 2019, time=2019-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1037953, encodeId=8900103e953cd, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Sun Dec 15 21:16:00 CST 2019, time=2019-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376997, encodeId=70843e6997a3, content=又多了一种新方法。, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43a21971117, createdName=njwbhuang, createdTime=Sun Dec 15 19:46:13 CST 2019, time=2019-12-15, status=1, ipAttribution=)]
    2020-09-28 minlingfeng
  4. [GetPortalCommentsPageByObjectIdResponse(id=1734194, encodeId=156d1e3419422, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Mon Nov 23 10:16:00 CST 2020, time=2020-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943244, encodeId=590f194324407, content=<a href='/topic/show?id=40875986ec9' target=_blank style='color:#2F92EE;'>#晚期肺腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59867, encryptionId=40875986ec9, topicName=晚期肺腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e72268, createdName=zhixianchen, createdTime=Fri Mar 20 05:16:00 CST 2020, time=2020-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865753, encodeId=0cb71865e53a1, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Sep 28 18:16:00 CST 2020, time=2020-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1935601, encodeId=a536193560172, content=<a href='/topic/show?id=53a3e82802' target=_blank style='color:#2F92EE;'>#ganetespib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7828, encryptionId=53a3e82802, topicName=ganetespib)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9cb02500048, createdName=ms6832696159214430, createdTime=Sun Apr 05 23:16:00 CST 2020, time=2020-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=377023, encodeId=e7173e7023fe, content=又一个失败了,Hsp90不易呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Mon Dec 16 08:53:04 CST 2019, time=2019-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1037953, encodeId=8900103e953cd, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Sun Dec 15 21:16:00 CST 2019, time=2019-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376997, encodeId=70843e6997a3, content=又多了一种新方法。, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43a21971117, createdName=njwbhuang, createdTime=Sun Dec 15 19:46:13 CST 2019, time=2019-12-15, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1734194, encodeId=156d1e3419422, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Mon Nov 23 10:16:00 CST 2020, time=2020-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943244, encodeId=590f194324407, content=<a href='/topic/show?id=40875986ec9' target=_blank style='color:#2F92EE;'>#晚期肺腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59867, encryptionId=40875986ec9, topicName=晚期肺腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e72268, createdName=zhixianchen, createdTime=Fri Mar 20 05:16:00 CST 2020, time=2020-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865753, encodeId=0cb71865e53a1, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Sep 28 18:16:00 CST 2020, time=2020-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1935601, encodeId=a536193560172, content=<a href='/topic/show?id=53a3e82802' target=_blank style='color:#2F92EE;'>#ganetespib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7828, encryptionId=53a3e82802, topicName=ganetespib)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9cb02500048, createdName=ms6832696159214430, createdTime=Sun Apr 05 23:16:00 CST 2020, time=2020-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=377023, encodeId=e7173e7023fe, content=又一个失败了,Hsp90不易呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Mon Dec 16 08:53:04 CST 2019, time=2019-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1037953, encodeId=8900103e953cd, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Sun Dec 15 21:16:00 CST 2019, time=2019-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376997, encodeId=70843e6997a3, content=又多了一种新方法。, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43a21971117, createdName=njwbhuang, createdTime=Sun Dec 15 19:46:13 CST 2019, time=2019-12-15, status=1, ipAttribution=)]
    2019-12-16 lovetcm

    又一个失败了,Hsp90不易呀

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1734194, encodeId=156d1e3419422, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Mon Nov 23 10:16:00 CST 2020, time=2020-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943244, encodeId=590f194324407, content=<a href='/topic/show?id=40875986ec9' target=_blank style='color:#2F92EE;'>#晚期肺腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59867, encryptionId=40875986ec9, topicName=晚期肺腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e72268, createdName=zhixianchen, createdTime=Fri Mar 20 05:16:00 CST 2020, time=2020-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865753, encodeId=0cb71865e53a1, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Sep 28 18:16:00 CST 2020, time=2020-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1935601, encodeId=a536193560172, content=<a href='/topic/show?id=53a3e82802' target=_blank style='color:#2F92EE;'>#ganetespib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7828, encryptionId=53a3e82802, topicName=ganetespib)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9cb02500048, createdName=ms6832696159214430, createdTime=Sun Apr 05 23:16:00 CST 2020, time=2020-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=377023, encodeId=e7173e7023fe, content=又一个失败了,Hsp90不易呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Mon Dec 16 08:53:04 CST 2019, time=2019-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1037953, encodeId=8900103e953cd, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Sun Dec 15 21:16:00 CST 2019, time=2019-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376997, encodeId=70843e6997a3, content=又多了一种新方法。, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43a21971117, createdName=njwbhuang, createdTime=Sun Dec 15 19:46:13 CST 2019, time=2019-12-15, status=1, ipAttribution=)]
    2019-12-15 anti-cancer

    谢谢梅斯分享这么多精彩信息

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1734194, encodeId=156d1e3419422, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Mon Nov 23 10:16:00 CST 2020, time=2020-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943244, encodeId=590f194324407, content=<a href='/topic/show?id=40875986ec9' target=_blank style='color:#2F92EE;'>#晚期肺腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59867, encryptionId=40875986ec9, topicName=晚期肺腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e72268, createdName=zhixianchen, createdTime=Fri Mar 20 05:16:00 CST 2020, time=2020-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865753, encodeId=0cb71865e53a1, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Sep 28 18:16:00 CST 2020, time=2020-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1935601, encodeId=a536193560172, content=<a href='/topic/show?id=53a3e82802' target=_blank style='color:#2F92EE;'>#ganetespib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7828, encryptionId=53a3e82802, topicName=ganetespib)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9cb02500048, createdName=ms6832696159214430, createdTime=Sun Apr 05 23:16:00 CST 2020, time=2020-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=377023, encodeId=e7173e7023fe, content=又一个失败了,Hsp90不易呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Mon Dec 16 08:53:04 CST 2019, time=2019-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1037953, encodeId=8900103e953cd, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Sun Dec 15 21:16:00 CST 2019, time=2019-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376997, encodeId=70843e6997a3, content=又多了一种新方法。, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43a21971117, createdName=njwbhuang, createdTime=Sun Dec 15 19:46:13 CST 2019, time=2019-12-15, status=1, ipAttribution=)]
    2019-12-15 njwbhuang

    又多了一种新方法。

    0

相关资讯

JAMA Oncol:免疫检查点抑制剂二线治疗NSCLC预后因素Meta分析

免疫检查点抑制剂替代多西他赛成为晚期NSCLC的标准二线治疗,但缺乏临床和分子特征的预后数据。纳入免疫检查点抑制剂(纳武单抗、派姆单抗或atezolizumab)对比多西他赛的随机对照研究。收集试验名称、发表时间、患者临床病理特征、化疗类型、免疫检查点抑制剂类型。

Best of ASCO 2018 China:胃肠肿瘤专场精彩回顾(2)—— S-1联合多西他赛对比S-1单药用于III期胃癌根治性手术后辅助治疗的随机对照

2018年7月5-8日,中国临床肿瘤学会(CSCO)联合美国临床肿瘤学会(ASCO)在合肥成功举办了“临床肿瘤学新进展学术研讨会——Best of ASCO(BOA)2018 China”。2天的时间,解读了39项研究摘要,12场专家点评,4个研究进展述评。来自全国各地2000余名专家学者,汇聚合肥,回顾研究进展,共同探讨和交流这些研究对我国临床实践的影响。以下分享胃肠肿瘤专场精彩内容。

CLIN CANCER RES:新辅助卡铂和多西他赛治疗的三阴性乳腺癌患者的病理缓解情况

三阴性乳腺癌(TNBC)需要可靠的能够预测新辅助化疗(NACT)反应的预测标志物。CLIN CANCER RES近期发表了一篇文章,评估TNBCtype-4分类在接受新辅助卡铂和多西他赛(Tcb)治疗的三阴性乳腺癌患者中预测治疗反应的能力。

JAMA Oncol:高RS评分早期乳腺癌患者接受内分泌联合辅助化疗可显著改善预后

对于RS评分26-100的早期乳腺癌患者,在辅助化疗基础上联合内分泌治疗后,5年无远端复发率可达到93%

CLIN CANCER RES:AZD1775联合新辅助多西他赛和顺铂治疗头颈部鳞状细胞癌

WEE1酪氨酸激酶调节G2-M转变并维持遗传稳定性,尤其在p53缺陷肿瘤中。头颈部鳞状细胞癌主要是因为肿瘤抑制因素缺失,因此需要探索WEE1抑制在其中发挥的作用。CLIN CANCER RES近期发表了一篇文章,研究WEE1抑制剂AZD1775联合顺铂和多西他赛的临床应用效果。

宋勇教授:超越化疗,阿帕替尼联合多西他赛二线治疗EGFR阴性NSCLC疗效初现

抗血管生成药物在晚期NSCLC患者的治疗中发挥着重要的作用,2018年WCLC大会报道了一项新型抗血管生成的小分子TKI阿帕替尼联合多西他赛二线治疗进展期EGFR阴性NSCLC患者的临床研究。试验发现,阿帕替尼联合多西他赛在获得理想临床疗效的同时,并未给患者带来更多的安全性问题。